Cargando…

Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia

BACKGROUND: Hyperkalemia (HK) is a barrier to optimization of renin-angiotensin-aldosterone system inhibitor (RAASi) therapy in heart failure (HF) and chronic kidney disease (CKD). We investigated cardiorenal risk associated with changes in RAASi regimen after an episode of HK in patients with HF an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kanda, Eiichiro, Rastogi, Anjay, Murohara, Toyoaki, Lesén, Eva, Agiro, Abiy, Arnold, Matthew, Chen, Gengshi, Yajima, Toshitaka, Järbrink, Krister, Pollack, Charles V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9854063/ https://www.ncbi.nlm.nih.gov/pubmed/36658531 http://dx.doi.org/10.1186/s12882-022-03054-5

Ejemplares similares

Management of RAASi-associated hyperkalemia in patients with cardiovascular disease
por: Silva-Cardoso, José, et al.
Publicado: (2021)

Association between hyperkalemia, RAASi non-adherence and outcomes in chronic kidney disease
por: Santoro, Antonio, et al.
Publicado: (2021)

Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan
por: Kashihara, Naoki, et al.
Publicado: (2019)

Impact of chronic potassium binder treatment on the clinical outcomes in patients with hyperkalemia: Results of a nationwide hospital-based cohort study
por: Kanda, Eiichiro, et al.
Publicado: (2023)

Clinical and Economic Burden of Hyperkalemia: A Nationwide Hospital-Based Cohort Study in Japan
por: Kanda, Eiichiro, et al.
Publicado: (2020)

Cardiovascular and Renal Outcomes Associated With Hyperkalemia in Chronic Kidney Disease: A Hospital-Based Cohort Study
por: Kohsaka, Shun, et al.
Publicado: (2021)

Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis
por: Montagnani, Andrea, et al.
Publicado: (2021)

Machine Learning Models Predicting Cardiovascular and Renal Outcomes and Mortality in Patients with Hyperkalemia
por: Kanda, Eiichiro, et al.
Publicado: (2022)

Medical Costs in Patients with Hyperkalemia on Long-Term Sodium Zirconium Cyclosilicate Therapy: The RECOGNIZE II Study
por: Agiro, Abiy, et al.
Publicado: (2023)

Course of Hyperkalemia in Patients on Hemodialysis
por: Spinowitz, Bruce, et al.
Publicado: (2022)

The prevalence of predialysis hyperkalemia and associated characteristics among hemodialysis patients: The RE‐UTILIZE study
por: Agiro, Abiy, et al.
Publicado: (2022)

Real-World Modifications of Renin-Angiotensin-Aldosterone System Inhibitors in Patients with Hyperkalemia Initiating Sodium Zirconium Cyclosilicate Therapy: The OPTIMIZE I Study
por: Agiro, Abiy, et al.
Publicado: (2023)

In-hospital mortality, length of stay, and hospitalization cost of COVID-19 patients with and without hyperkalemia
por: Amin, Alpesh, et al.
Publicado: (2022)

Impact of Sodium Zirconium Cyclosilicate Plus Renin–Angiotensin–Aldosterone System Inhibitor Therapy on Short-Term Medical Costs in Hyperkalemia: OPTIMIZE II Real-World Study
por: Dwyer, Jamie P., et al.
Publicado: (2023)

Patiromer and maintenance of RAASi therapy in hyperkalemic medicare patients
por: Desai, Nihar R., et al.
Publicado: (2019)

Effectiveness of Sodium Zirconium Cyclosilicate in Hemodialysis Patients With Severe Hyperkalemia
por: Ford, Martin, et al.
Publicado: (2021)

Liver Disease Is a Risk Factor for Recurrent Hyperkalemia: A Retrospective Cohort Study
por: Ahdoot, Rebecca S., et al.
Publicado: (2023)

The Increased Clinical and Economic Burden of Hyperkalemia in Medicare Patients Admitted to Long-Term Care Settings
por: Neuenschwander, James F., et al.
Publicado: (2023)

Discontinuation of Renin-Angiotensin-Aldosterone System Inhibitors Secondary to Hyperkalemia Translates into Higher Cardiorenal Outcomes
por: An, Jaejin, et al.
Publicado: (2023)

The value of maintaining normokalaemia and enabling RAASi therapy in chronic kidney disease
por: Evans, Marc, et al.
Publicado: (2019)

Comment on Montagnani et al. Optimization of RAASi Therapy with New Potassium Binders for Patients with Heart Failure and Hyperkalemia: Rapid Review and Meta-Analysis. J. Clin. Med. 2021, 10, 5483
por: Zarzuela, Donna, et al.
Publicado: (2022)

Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia
por: Kohsaka, Shun, et al.
Publicado: (2022)

Association of Hyperkalemia and Hypokalemia with Patient Characteristics and Clinical Outcomes in Japanese Hemodialysis (HD) Patients
por: Iwagami, Masao, et al.
Publicado: (2023)

Correction: Kohsaka et al. Risk–Benefit Balance of Renin–Angiotensin–Aldosterone Inhibitor Cessation in Heart Failure Patients with Hyperkalemia. J. Clin. Med. 2022, 11, 5828
por: Kohsaka, Shun, et al.
Publicado: (2023)

Prescription of renin‐angiotensin‐aldosterone system inhibitors (RAASi) and its determinants in patients with advanced CKD under nephrologist care
por: Pecoits‐Filho, Roberto, et al.
Publicado: (2019)

RAASi Therapy Attenuates the Association between 24-h Urinary Potassium Excretion and Dietary Potassium Intake in CKD Patients
por: Giannese, Domenico, et al.
Publicado: (2023)

Machine learning models for prediction of HF and CKD development in early-stage type 2 diabetes patients
por: Kanda, Eiichiro, et al.
Publicado: (2022)

Determinants of Hyperkalemia Progression Among Patients with Mild Hyperkalemia
por: Israni, Rubeen, et al.
Publicado: (2021)

Rationale and design of CONTINUITY: a Phase 4 randomized controlled trial of continued post-discharge sodium zirconium cyclosilicate treatment versus standard of care for hyperkalemia in chronic kidney disease
por: Burton, James O, et al.
Publicado: (2023)

A phase 3 multicenter open-label maintenance study to investigate the long-term safety of sodium zirconium cyclosilicate in Japanese subjects with hyperkalemia
por: Kashihara, Naoki, et al.
Publicado: (2020)

Hyperkalemia and Rhabdomyolyssis
por: Yasri, Sora, et al.
Publicado: (2015)

Correction of serum potassium with sodium zirconium cyclosilicate in Japanese patients with hyperkalemia: a randomized, dose–response, phase 2/3 study
por: Kashihara, Naoki, et al.
Publicado: (2020)

Antibiotic dispensing following pediatric visits in the US emergency departments and outpatient settings from 2006 to 2016
por: Agiro, Abiy, et al.
Publicado: (2019)

Do Acupuncture Services Reduce Subsequent Utilization of Opioids and Surgical Interventions Compared to Noninvasive Therapies among Patients with Pain Conditions?
por: Pham, Timothy, et al.
Publicado: (2021)

Hyperkalemia among hospitalized patients and association between duration of hyperkalemia and outcomes
por: Khanagavi, Jagadish, et al.
Publicado: (2014)

Hyperkalemia Among Hospitalized Patients and Association Between Duration of Hyperkalemia and Outcomes
por: Alrashidi, Tahani Nasser, et al.
Publicado: (2020)

Sliding with the sines − fatal hyperkalemia: A case report
por: Soe, Kyaw Khaing, et al.
Publicado: (2021)

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure
por: Ward, Thomas, et al.
Publicado: (2023)

Chart validation of an algorithm for identifying hereditary progressive muscular dystrophy in healthcare claims
por: Chen, Xiaoxue, et al.
Publicado: (2019)

An unusual manifestation of hyperkalemia
por: Belkouch, Ahmed, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_669304ti0s13oabs36p4up7sh3